|
Authors | Age/gender | Race | Site of lesion | IHC | Stage | Surgery | Radiation | Chemotherapy | Survival/recurrence |
|
Hajiioannou et al. [6] | 33/M | NR | Nasal cavity, ethmoid sinus with frontal lobe invasion | +p40, rare focal | T4bN0M0 stage IVB | No | 66 Gy | 5-fluorouracil and cisplatin | Complete tumor response |
+p63, rare focal + EBV |
+Cytokeratins |
MNF116 and EMA |
|
Rytkönen et al. [12] | 30/M | NR | Maxillary sinus, soft palate/uvula with regional LN metastases | +Cytokeratin | T2N0M0 stage II | Yes | 70 Gy | Cisplatin | 11-month follow-up, no recurrence |
+CD45 (among lymphoplasmacytic infiltrate) |
+AE1/AE3 |
−EBV |
|
Tam et al. [13] | 61/F | NR | Nasolacrimal duct | +EBV | NR | Enbloc resection with medial maxillectomy | 64 Gy | No | 33-month follow-up, no recurrence |
|
Takakura et al. [14] | 63/M | Japanese | Maxillary sinus | +Pancytokeratin, cytokeratin 14 | T3N2bM0 stage IVA | Denker’s operation | 36 + 34 Gy | 5-Fluorouracil and nedaplatin | Disease-free for 5 years following operation |
+EBV |
|
Mohammed et al. [8] | 72/F | Caucasian | Maxillary sinus | +Pancytokeratin marker (MF116) +CK5/6, slight | T1N0M0 stage I | Radical excision of the mass | 48 Gy | No | 3-years follow-up, no recurrence |
−CK7, CEA, Melan, CK20, EBV |
|
Jung et al. [15] | 64/F | Asian | Maxillary sinus | +Pancytokeratin | T3N0M0 stage III | Enbloc sparing periorbita | 6300 cGy | Docetaxel and carboplatin | 3-year-follow-up, no recurrence |
−EBV |
|
Muthayam et al. [16] | 45/F | Indian | Maxillary sinus with LN metastases | +Pancytokeratin, diffuse | T3N0M0 stage III | No | 70 Gy | No | 20-month follow-up, no recurrence |
−Melanin A, CK20, EBV |
|
Kim et al. [17] | 21/M | NR | Nasal cavity | +Cytokeratin, CK5/6 | T2N0M0 stage II | Endoscopic surgical excision | IMRT, 6996 cGy | Cisplatin | 15-month follow-up, no recurrence |
+EBV |
|
Mahawar and Devi [4] | 76/M | NR | Maxillary sinus | +Cytokeratin | NR | No | EBRT, 7000 cGy | No | Currently under treatment |
|
Rahim et al. [18] | 32/F | Chinese | Nasopharynx | +MNF 116 | NR | Endoscopic excision | NR | NR | NR |
+EBV |
|
Wöckel and Wernert [19] | 56/M | NR | Meatus of the nose | +Keratin | T1N0M0 stage I | Excision | No | No | No recurrence |
−EBV |
|
Bonnerup et al. [10] | 77/M | Caucasian | Sinonasal | +Pankeratin | T4aN2cMI stage IVC | NR | NR | Cisplatin and docetaxel | Excellent tumor response after two cycles |
+CK5/6 |
+EMA (patchy) |
+EBV, strong and diffuse |
|
Trabelsi et al. [9] | 58/M | Tunisian | Nasal septum with orbital invasion | +Cytokeratin, EMA | T3N0M0 stage III | No | 72 Gy | Adriamycin and cisplatin | 12-month follow-up, no recurrence |
+EBV latent membrane protein 1 |
|